Regenxbio Inc (NAS:RGNX)
$ 9.92 -0.09 (-0.9%) Market Cap: 491.49 Mil Enterprise Value: 320.09 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 65/100

Q2 2019 Regenxbio Inc Earnings Call Transcript

Aug 07, 2019 / 08:30PM GMT
Release Date Price: $40.54 (-1.36%)
Operator

Good afternoon and welcome to the REGENXBIO Second Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to Ms. Sara Garon Berl, Vice President for Law and Policy for REGENXBIO. You may begin.

Sara Garon Berl
REGENXBIO Inc. - VP of Law and Policy

Good afternoon and thank you for joining us today. With us today are Ken Mills, REGENXBIO's President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and Vit Vasista, our Chief Financial Officer.

Earlier this afternoon REGENXBIO released financial and operating results for the 3 months ended June 30, 2019. The press release reporting our financial results is available on our website at www.regenxbio.com.

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot